Erectile dysfunction: Science and medicine

Annual Review of Sex Research

Volumn 17, Issue , 2006, Pages 101-115

  Burnett, Arthur L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Gene therapy; Growth factor; Nitric oxide; Penile erection; Penis; Phosphodiesterase

Indexed keywords

EID: 49449114101     PISSN: 10532528     EISSN: None     Source Type: Journal    
DOI: 10.1080/10532528.2006.10559838     Document Type: Article

References (39)

1. Argiolas, A., & Melis, M. R. (2005). Central control of penile erection: Role of the paraventricular nucleus of the hypothalamus. Progress in Neurobiology, 76, 1-21.
2. Burnett, A. L. (2003). Neuroprotection and nerve grafts in the treatment of neurogenic erectile dysfunction. Journal of Urology, 170, S31-S34.
3. Burnett, A. L. (2006). Erectile dysfunction. Journal of Urology, 175, S25-S31.
4. Burnett, A. L., & Musicki, B. (2005). The nitric oxide signaling pathway in the penis. Current Pharmaceutical Design, 11, 3987-3994.
5. Christ, G. J. (1995). The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. The Urologie Clinics of North America, 22, 727-745.
6. Christ, G. J. (2000). Gene therapy: Future strategies and therapies. Drugs Today, 36, 175-184.
7. Corbin, J. D. (2004). Mechanisms of action of PDE5 inhibition in erectile dysfunction. International Journal of Impotence Research, /6(Suppl. 1), S4-S7.
8. DeBusk, R., Drory, Y., Goldstein, I., Jackson, G., Kaul, S., Kimmel, S. E., et al. (2000). Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of the Princeton Consensus Panel. American Journal of Cardiology, 86, 62F-68F.
9. DiSanto, M. E. (2005). Contractile mechanisms in diabetes-related erectile dysfunction. Current Pharmaceutical Design, 11, 3995-4010.
10. Fournier, G. R., Jr., Juenemann, K. P., Lue, T. F., & Tanagho, E. A. (1987). Mechanisms of venous occlusion during canine penile erection: An anatomic demonstration. Journal of Urology, 137, 163-167.
11. Guay, A. T., Perez, J. B., Jacobson, J., & Newton, R. A. (2001). Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. Journal of'Andrology, 22, 793-797.
12. Hatzichristou, D. (2005). Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): Coincidence or causality? Journal of Sexual Medicine, 2, 751-758.
13. Jackson, G. (2005). Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. American Journal of Cardiology, 96, 32M-36M.
14. Jin, L., & Burnett, A. L. (2006). RhoA/Rho-kinase in erectile tissue: Mechanisms of disease and therapeutic insights. Clinical Science (London), 110, 153-165.
15. Kalsi, J. S., Rees, R. W., Hobbs, A. J., Royle, M., Kell, P. D., Ralph, D. J., et al. (2003). BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. Journal of Urology, 169, 761-766.
16. Katz, S. D., Parker, J. D., Glasser, D. B., Bank, A. J., Sherman, N., Wang, H., et al (2005). Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. American Journal of Cardiology, 95, 36-42.
17. Kirby, M., Jackson, G., & Simonsen, U. (2005). Endothelial dysfunction links erectile dysfunction to heart disease. International Journal of Clinical Practice, 59, 225-229.
18. Kloner, R. A. (2005). Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: Focus on alpha-blocker interactions. American Journal of Cardiology, 96, 2M-46M.
19. Kloner, R. A., Jackson, G., Hutter, A. M., Mittleman, M. A., Chan, M., Warner, M. R., et al. (2006). Cardiovascular safety update to Tadalafil: Retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. American Journal of Cardiology, 97, 1778-1784.
20. Kostis, J. B., Jackson, G., Rosen, R., Barrett-Connor, E., Billups, K., Burnett, A. L., et al. (2005). Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). American Journal of Cardiology, 96, 313-321.
21. Kwon, T G., Yoo, J. J., & Atala, A. (2002). Autologous penile corpora cavernosa replacement using tissue engineering techniques. Journal of Urology, 168, 1754-1758.
22. Laties, A., & Sharlip, I. (2006). Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. Journal of Sexual Medicine, 3, 12-27.
23. Lue, T. F., Takamura, T, Schmidt, R. A., Palubinskas, A. J., & Tanagho, E. A. (1983). Hemodynamics of erection in the monkey. Journal of Urology, 130, 1237-1241.
24. McVary, K. (2006). Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology. British Journal of Urology International, 97(Suppl. 2), 23-28.
25. Melman, A., Bar-Chama, N., McCullough, A., Davies, K., & Christ, G. (2005). The first human trial for gene transfer therapy for the treatment of erectile dysfunction: Preliminary results. European Urology, 48, 314-318.
26. Mittleman, M. A., Glasser, D. B., & Orazem, J. (2003). Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. International Journal of Clinical Practice, 57, 597-600.
27. Montague, D. K., Jarow, J. P., Broderick, G. A., Dmochowski, R. R., Heaton, J. P., Lue, T. F., et al. (2005). Chapter 1: The management of erectile dysfunction: An AUA update. Journal of Urology, 174, 230-239.
28. Moreland, R. B., Patel, M., Hsieh, G. C, Wetter, J. M., Marsh, K., & Brioni, J. D. (2005). A-412997 is a selective dopamine D4 receptor agonist in rats . Pharmacology, Biochemistry, and Behavior, 82, 140-147.
29. Morelli, A., Filippi, S., Mancina, R., Luconi, M., Vignozzi, L., Marini, M., et al. (2004). Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology, 145, 2253-2263.
30. NIH Consensus Development Panel on Impotence. (1993). NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA, 270, 83-90.
31. Padma-Nathan, H., Christ, G., Adaikan, G., Becher, E., Brock, G., Carrier, S., et al. (2004). Pharmacotherapy for erectile dysfunction. Journal of Sexual Medicine, 1, 128-140.
32. The Process of Care Consensus Panel. (1999). The process of care model for evaluation and treatment of erectile dysfunction. International Journal of Impotence Research, 11, 59-70.
33. Rajfer, J. (2004). Endothelial dysfunction as a cause of erectile dysfunction-Misdiagnosis or misnomer? Urology, 64, 193-194.
34. Rosen, R. C, Diamond, L. E., Earle, D. C, Shadiack, A. M., & Molinoff, P. B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research, 16, 135-142.
35. Saenz de Tejada, I., Angulo, J., Cellek, S., Gonzalez-Cadavid, N., Heaton, J., Pickard, R., et al. (2004). Physiology of erectile dysfunction. Journal of Sexual Medicine, 1, 254-265.
36. Shabsigh, R. (2005). Testosterone therapy in erectile dysfunction and hypogonadism. Journal of Sexual Medicine, 2, 785-792.
37. Shabsigh, R., Kaufman, J. M., Steidle, C, & Padma-Nathan, H. (2004). Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology, 172, 658-663.
38. Siroky, M. B., & Azadzoi, K. M. (2003). Vasculogenic erectile dysfunction: Newer therapeutic strategies. Journal of Urology, 170, S24-S29.
39. Thadani, U., Smith, W., Nash, S., Bittar, N., Glasser, S., Narayan, P., et al. (2002). The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. Journal of American College of Cardiology, 40, 2006-2012.